/publications/issue/2012/Generic-Supplement-2012/Watson-Pharmaceuticals-Leading-the-Generic-Industry-in-Product-Portfolio-Quality-and-Customer-Service

Watson Pharmaceuticals: Leading the Generic Industry in Product Portfolio, Quality, & Customer Service

Author:



Watson Pharmaceuticals, Inc. (NYSE: WPI) is a leading integrated global pharmaceutical company engaged in the development, manufacturing, marketing, sale, and distribution of generic, brand, and biologic products.

A Focus on Quality Generics
With more than 190 US generic products, Watson’s global generics business is focused on maintaining a leading position within the US generics market, where it is ranked third in number of prescriptions dispensed annually. Our portfolio of generic products includes antibiotics, antiinflammatories, depression, extended-release, hypertension, oral contraceptives, pain management, smoking cessation, and more.

First to Bring Key Generics to Market
In 2011, we expanded our US generics product line with the launch of 16 products. In addition to the generic versions of CONCERTA® (methylphenidate HCl extended release) and LIPITOR® (atorvastatin calcium), we launched generics of Famvir® (famciclovir), KADIAN® (morphine sulfate extended release), Keppra XR® (levetiracetam extended-release), and new oral contraceptives including Amethia® (a generic version of SEASONIQUE® [levonorgestrel/ethinyl estradiol]), Amethia® Lo (a generic version of Lo SEASONIQUE® [levonorgestrel/ethinyl estradiol]), and Amethyst® (a generic version of Lybrel® [ethinyl estradiol/levonorgestrel]). In 2011, we had 36% share in the US market in generic oral contraceptives with more than 30 product formulations.

During 2011, we announced the initiation of a number of patent challenges, including challenges to OxyContin® (oxycodone HCl), Vigamox® (moxifloxacin HCl ophthalmic solution), Welchol® (colesevelam HCl), Viagra® (sildenafil citrate), Pataday™ (olapatadine HCl ophthalmic), AVODART® (dutasteride), Vyvanse® (lisdexamfetamine dimesylate), JALYN™ (dutasteride & tamsulosin), EMBEDA® (morphine sulfate & naltrexone HCl), Daytrana® (methylphenidate transdermal system), Atelvia™ (risedronate sodium delayed-release), and Exelon® (rivastigmine transdermal system).

Global Supply Chain Ensures Top Customer Service
Our long-term success is predicated on our commitment to providing the highest levels of customer service around the world, and our industry-leading, integrated global supply chain is focused on realizing this commitment, from product development through on-time launch and delivery of commercial supply in all of our markets. Ensuring Continued Value for Our Customers & Patients We are committed to ensuring continued value for our customers and patients. We are focused on the development and commercialization of more complex products, including moving beyond modified-release solid-dosage products into complex transdermals, topicals, and ophthalmics, as well as semi-solid, inhalation, and complex injectable products.

Expanding Globally
On April 25, 2012, we announced that we had entered into a definitive agreement to acquire privately held Actavis. As a result of this proposed acquisition, which is expected to close in the fourth quarter of 2012, Watson will become the third largest global generics company. The combined company will hold a top 3 position in 12 markets and a top 5 market position in 15 markets. The proposed transaction achieves Watson’s stated objective of expanding and diversifying our business into a truly global company.

A Mission that Matters
Every day, our more than 7500 scientists, technicians, sales and marketing, administrative, manufacturing, and business professionals work together to achieve our global mission: helping others achieve a better quality of life.



For more information, visit www.watson.com.